CMS Should Shift 75% Of Pass-Through Costs To APCs - AdvaMed
This article was originally published in The Gray Sheet
Executive Summary
By moving at least 75% of device costs from "pass-through" payments to the base ambulatory payment classification (APC) rates, the Centers for Medicare & Medicaid Services can soften the impact of future pro-rata cuts, according to AdvaMed.
You may also be interested in...
AdvaMed Urges Pro-Rata Delay, Says 80% Of OPPS Claims Data Is Missing
CMS should delay a pro-rata reduction on pass-through payments for devices under the outpatient prospective payment system (OPPS) because nearly 80% of its claims data is unnaccounted for, AdvaMed asserts in its most recent attempt to prevent the agency from making the cuts in 2002.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.